Maxillary Sinusitis, Sinusitis, Sinusitis, Acute
Conditions
Keywords
adult, endoscopic sinus surgery
Brief summary
The aim of this study is to find out if endoscopic sinus surgery improves the quality of life in patients suffering from recurrent acute rhinosinusitis. Our main outcome is the difference between the average change in disease-specific SNOT-22 quality of life questionnaire scores (from baseline to 5-6 months follow-up) between the intervention and the control groups.
Detailed description
This is a randomized controlled trial. Patients suffering from recurrent acute sinusitis episodes will be randomly allocated to two groups: intervention group, where they will receive endoscopic sinus surgery in addition to medical treatment and control group, where they will receive mere medical treatment. Both groups will be followed-up for 5 to 6 months. At baseline and after 5 to 6 months, patients will answer the life quality questionnaires SNOT-22 and RAND 36-item Health Survey. The numbers of sinusitis episodes, medical appointments for respiratory symptoms, use of medications, numbers of days lost from work or studies and numbers of days with various respiratory and adverse symptoms will be recorded with patient diaries. The potential serious adverse events (e.g. cerebrospinal fluid leak, orbital complications) related to surgery will be collected from the medical records.
Interventions
PROCEDUREEndoscopic sinus surgery (ESS)
Uncinectomy, middle meatal antrostomy by enlarging the natural maxillary ostium and partial ethmoidectomy or septoplasty according to clinical evaluation of the operator.
Sponsors
Tampere University Hospital
Oulu University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* At least 3 acute sinusitis episodes during previous 6 months or 4 acute sinusitis episodes during previous 12 months or at least 2 episodes per year for 3 consecutive years * Episodes must last less than 4 weeks and be diagnosed and treated as acute rhinosinusitis by a physician * Episode symptoms include nasal discharge, nasal congestion, hyposmia and facial pressure or pain and the episodes have to be severe enough for the patient to seek medical help and for daily life to be significantly disturbed * Patients must have failed a three-month conservative therapy (medication for possible allergies, nasal corticosteroids and douching and courses of antibiotics as necessary)
Exclusion criteria
* Age under 18 years, * Immunodeficiency or immunosuppression * Pregnancy, * Previous illness making same-day surgery unfeasible * Ongoing antibiotic treatment for other reasons, * Primary complaint of nasal septal deviation and * Chronic rhinosinusitis with or without nasal polyposis * Symptoms for over 12 weeks and/or Lund-Mackay score over 8 in paranasal sinus CBCT scanning
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sinonasal Outcome Test-22 score | 5-6 months | Difference between the mean disease-specific Sinonasal Outcome Test 22 (SNOT-22) change scores (from baseline to 5-6 months) of ESS and control group. SNOT-22 summary scores vary between 0 and 110 with higher values indicating poorer quality of life. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference in proportions of patients benefiting | 5-6 months | Difference in proportions of patients benefiting clinically significantly from the treatment in ESS and control group (Minimum important change in SNOT-22 score) |
| Difference in numbers of sinusitis episodes | 5-6 months | Difference in the numbers of sinusitis episodes between the ESS and control groups. |
| Difference in numbers of medical visits | 5-6 months | Difference in the numbers of medical visits between the ESS and control groups. |
| Difference in numbers of antimicrobial treatments | 5-6 months | Difference in the numbers of antimicrobial treatments between the ESS and control groups. |
| Difference in numbers of days lost from work or studies | 5-6 months | Difference in the numbers of days lost from work or studies between the ESS and control groups. |
| Difference in numbers of days with nasal obstruction | 5-6 months | Difference in the numbers of days with nasal obstruction between the ESS and control groups. |
| Difference in numbers of days with nasal discharge | 5-6 months | Difference in the numbers of days with nasal discharge between the ESS and control groups. |
| 36-Item Short Form Survey (SF-36, RAND) score | 5-6 months | Difference between the mean generic RAND-36 domains change scores (from baseline to 5-6 months) of ESS and control group. RAND-36 instrument produces eight individual values between 0 and 100 (one for each domain), with higher scores indicating better quality of life. |
| Difference in numbers of days with nasal pain | 5-6 months | Difference in the numbers of days with nasal pain between the ESS and control groups. |
| Difference in numbers of days with nasal hemorrhage | 5-6 months | Difference in the numbers of days with nasal hemorrhage between the ESS and control groups. |
| Difference of numbers of days with fever | 5-6 months | Difference in the numbers of days with fever (\>37.5 Celsius) between the ESS and control groups. |
| Adverse effects - postoperative synechia formation | 5-6 months | Frequency of postoperative synechia formations in the ESS group |
| Adverse effects - postoperative infection | 5-6 months | Frequency of postoperative infections in the ESS group |
| Adverse effects - postoperative orbital complication | 5-6 months | Frequency of postoperative orbital complications in the ESS group |
| Adverse effects - postoperative intracranial complication | 5-6 months | Frequency of postoperative intracranial complications in the ESS group |
| Difference in numbers of days with facial pain or pressure | 5-6 months | Difference in the numbers of days with facial pain or pressure between the ESS and control groups. |
Countries
Finland
Contacts
Primary ContactHeidi M Kaski, MD
Outcome results
None listed